Literature DB >> 10362804

Immunohistological analysis of in situ expression of mycobacterial antigens in skin lesions of leprosy patients across the histopathological spectrum. Association of Mycobacterial lipoarabinomannan (LAM) and Mycobacterium leprae phenolic glycolipid-I (PGL-I) with leprosy reactions.

C Verhagen1, W Faber, P Klatser, A Buffing, B Naafs, P Das.   

Abstract

The presence of mycobacterial antigens in leprosy skin lesions was studied by immunohistological methods using monoclonal antibodies (MAbs) to Mycobacterium leprae-specific phenolic glycolipid I (PGL-I) and to cross-reactive mycobacterial antigens of 36 kd, 65 kd, and lipoarabinomannan (LAM). The staining patterns with MAb to 36 kd and 65 kd were heterogeneous and were also seen in the lesions of other skin diseases. The in situ staining of PGL-I and LAM was seen only in leprosy. Both antigens were abundantly present in infiltrating macrophages in the lesions of untreated multibacillary (MB) patients, whereas only PGL-I was occasionally seen in scattered macrophages in untreated paucibacillary lesions. During treatment, clearance of PGL-I from granulomas in MB lesions occurred before that of LAM, although the former persisted in scattered macrophages in some treated patients. This persistence of PGL-I in the lesions paralleled high serum anti-PGL-I antibody titers but was not indicative for the presence of viable bacilli in the lesions. Interestingly, we also observed a differential expression pattern of PGL-I and LAM in the lesions of MB patients with reactions during the course of the disease as compared with those without reactions. In conclusion, the in situ expression pattern of PGL-I and LAM in MB patients may assist in early diagnosis of reactions versus relapse.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10362804      PMCID: PMC3277205          DOI: 10.1016/S0002-9440(10)65435-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

1.  Use of NASBA RNA amplification for detection of Mycobacterium leprae in skin biopsies from untreated and treated leprosy patients.

Authors:  G M van der Vliet; S N Cho; K Kampirapap; J van Leeuwen; R A Schukkink; B van Gemen; P K Das; W R Faber; G P Walsh; P R Klatser
Journal:  Int J Lepr Other Mycobact Dis       Date:  1996-12

2.  IgG response to purified 65- and 70-kDa mycobacterial heat shock proteins and to antigen 85 in leprosy.

Authors:  P Launois; M N'Diaye Niang; A Drowart; J P Van Vooren; J L Sarthou; T Lalu; J Millan; K Huygen
Journal:  Int J Lepr Other Mycobact Dis       Date:  1994-03

3.  Serological monitoring of the response to chemotherapy in leprosy patients.

Authors:  P W Roche; W J Britton; S S Failbus; K D Neupane; W J Theuvenet
Journal:  Int J Lepr Other Mycobact Dis       Date:  1993-03

4.  CD1-restricted T cell recognition of microbial lipoglycan antigens.

Authors:  P A Sieling; D Chatterjee; S A Porcelli; T I Prigozy; R J Mazzaccaro; T Soriano; B R Bloom; M B Brenner; M Kronenberg; P J Brennan
Journal:  Science       Date:  1995-07-14       Impact factor: 47.728

5.  Analysis of T-cell and B-cell responses to recombinant M. leprae antigens in leprosy patients and in healthy contacts: significant T-cell responses to antigens in M. leprae nonresponders.

Authors:  J E Thole; A A Janson; A Kifle; R C Howe; K McLean; A Nurilygn; E Filley; E J Shannon; G J Bulla; J Hermans
Journal:  Int J Lepr Other Mycobact Dis       Date:  1995-09

6.  CD1c restricts responses of mycobacteria-specific T cells. Evidence for antigen presentation by a second member of the human CD1 family.

Authors:  E M Beckman; A Melián; S M Behar; P A Sieling; D Chatterjee; S T Furlong; R Matsumoto; J P Rosat; R L Modlin; S A Porcelli
Journal:  J Immunol       Date:  1996-10-01       Impact factor: 5.422

Review 7.  Type 1 reaction, neuritis and disability in leprosy. What is the current epidemiological situation?

Authors:  C Lienhardt; P E Fine
Journal:  Lepr Rev       Date:  1994-03       Impact factor: 0.537

Review 8.  Immunological and functional characterization of Mycobacterium leprae protein antigens: an overview.

Authors:  J E Thole; B Wieles; J E Clark-Curtiss; T H Ottenhoff; T F Rinke de Wit
Journal:  Mol Microbiol       Date:  1995-12       Impact factor: 3.501

9.  T-cell stimulation with purified mycobacterial antigens in patients and healthy subjects infected with Mycobacterium leprae: secreted antigen 85 is another immunodominant antigen.

Authors:  P Launois; M N Niang; J L Sarthou; F Rivier; A Drowart; J P Van Vooren; J Millan; K Huygen
Journal:  Scand J Immunol       Date:  1993-08       Impact factor: 3.487

10.  Immunohistological localization of mycobacterial antigens within the peripheral nerves of treated leprosy patients and their significance to nerve damage in leprosy.

Authors:  V P Shetty; M W Uplekar; N H Antia
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

View more
  9 in total

1.  Comparison of the T cell patterns in leprous and cutaneous sarcoid granulomas. Presence of Valpha24-invariant natural killer T cells in T-cell-reactive leprosy together with a highly biased T cell receptor Valpha repertoire.

Authors:  M Mempel; B Flageul; F Suarez; C Ronet; L Dubertret; P Kourilsky; G Gachelin; P Musette
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Complement activation in leprosy: a retrospective study shows elevated circulating terminal complement complex in reactional leprosy.

Authors:  N Bahia El Idrissi; S Hakobyan; V Ramaglia; A Geluk; B Paul Morgan; P Kumar Das; F Baas
Journal:  Clin Exp Immunol       Date:  2016-03-31       Impact factor: 4.330

3.  Serological diagnosis of leprosy in patients in vietnam by enzyme-linked immunosorbent assay with Mycobacterium leprae-derived major membrane protein II.

Authors:  Masanori Kai; Nhu Ha Nguyen Phuc; Thuy Huong Hoang Thi; An Hoang Nguyen; Yasuo Fukutomi; Yumi Maeda; Yuji Miyamoto; Tetsu Mukai; Tsuyoshi Fujiwara; Tan Thanh Nguyen; Masahiko Makino
Journal:  Clin Vaccine Immunol       Date:  2008-10-22

4.  M. leprae components induce nerve damage by complement activation: identification of lipoarabinomannan as the dominant complement activator.

Authors:  Nawal Bahia El Idrissi; Pranab K Das; Kees Fluiter; Patricia S Rosa; Jeroen Vreijling; Dirk Troost; B Paul Morgan; Frank Baas; Valeria Ramaglia
Journal:  Acta Neuropathol       Date:  2015-03-15       Impact factor: 17.088

5.  In Situ complement activation and T-cell immunity in leprosy spectrum: An immunohistological study on leprosy lesional skin.

Authors:  Nawal Bahia El Idrissi; Anand M Iyer; Valeria Ramaglia; Patricia S Rosa; Cleverson T Soares; Frank Baas; Pranab K Das
Journal:  PLoS One       Date:  2017-05-15       Impact factor: 3.240

Review 6.  Immunohistochemical diagnosis of human infectious diseases: a review.

Authors:  Hamadou Oumarou Hama; Gérard Aboudharam; Rémi Barbieri; Hubert Lepidi; Michel Drancourt
Journal:  Diagn Pathol       Date:  2022-01-30       Impact factor: 2.644

7.  Leprosy: a review of laboratory and therapeutic aspects--part 2.

Authors:  Joel Carlos Lastória; Marilda Aparecida Milanez Morgado de Abreu
Journal:  An Bras Dermatol       Date:  2014 May-Jun       Impact factor: 1.896

8.  Anti-Lipoarabinomannan-Specific Salivary IgA as Prognostic Marker for Leprosy Reactions in Patients and Cellular Immunity in Contacts.

Authors:  André Alan Nahas; Mayara Ingrid de Sousa Lima; Isabela Maria Bernardes Goulart; Luiz Ricardo Goulart
Journal:  Front Immunol       Date:  2018-05-30       Impact factor: 7.561

9.  Differential Expression of IFN-γ, IL-10, TLR1, and TLR2 and Their Potential Effects on Downgrading Leprosy Reaction and Erythema Nodosum Leprosum.

Authors:  Douglas Eulálio Antunes; Isabela Maria Bernardes Goulart; Mayara Ingrid Sousa Lima; Patrícia Terra Alves; Paula Cristina Brígido Tavares; Luiz Ricardo Goulart
Journal:  J Immunol Res       Date:  2019-11-07       Impact factor: 4.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.